Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Indiana Biosciences Research Institute (IBRI) seeks a student intern in project coordination, operations, research administration, or strategy to help teams stay organized, track progress, and move projects forward. The program runs May 17, 2027 – August 6, 2027, at 35 hours per week.
Stipend: $9,650 for the full program, disbursed bi-weekly. Responsibilities include documenting systems, improving processes, data quality, and creating dashboards.
IBRI is poised to transform life sciences— and for millionsof people, even life itself.
IBRI is seeking a student interested in projectcoordination, operations, research administration, or strategy. The intern willhelp teams stay organized, track progress, and move projects forward.
May 17, 2027 – August 6, 2027
Applications will be acceptedthrough November 30, 2026. For priority consideration, apply by October 15,2026.
35 hours per week
This internship includes a stipend of$9,650 for the full program, disbursed in bi-weekly installments on or beforethe 7th and 22nd of each month
The Indiana Biosciences Research Institute (IBRI) is afirst-in-class translational medicine institute dedicated to advancing lifesciences in the race to eliminate disease and improve human health and life.
By connecting early-stage biotech companies withcutting-edge life science discoveries —and backed by the mission and resourcesof industry leaders, investors, and philanthropic partners—IBRI is successfullyevolving a new, independent model to conquer disease, uniting previouslyfragmented forces in the quest for cures.
Carefully curating and supporting early-stage companieswith investment, talent, and space, IBRI strategically accelerates drugdiscovery. Our work benefits from the relatively low cost of living and doingbusiness here, allowing more resources to be directed toward science.
Fueled by the same entrepreneurial creativity as thegroundbreaking scientific work we support, IBRI’s labs advance research acrossthe frontiers of diabetes, metabolic disease, Alzheimer’s disease, and rarepediatric diseases. Our ambitious public–private vision cultivates talent whileefficiently bridging the gap between research-driven inquiry and profit-drivendrug development.
At IBRI, cures are launched on a clear pathway to clinicaltrials, enabled by the combined resources and experience of our academic andindustry partners, without the typical pressure to deliver rapid results forcommercialization. IBRI labs pursue breakthroughs that might never happenelsewhere. Breakthroughs are happening here. Our novel financing model ensuresthat when discoveries are ready for clinical trials, the intellectual propertyis sold back to industry or spun off, creating a direct stream of revenue.
By every measure, the IBRI model demonstrates a novelapproach that delivers rewards. Scientific bench work is nurtured, drugdiscovery is advanced, workforce development is continuous, investors seereturns, and donors see impact. Most importantly, IBRI’s structure andportfolio of accomplishments matter to the patients whose lives are improved—oreven saved—by this forward-looking approach to life sciences.
IBRI is driven to bring next-generation therapies to marketwith an understanding of the complex pressures that often bind innovation toeconomics. After more than a decade, the evidence is clear: IBRI is poised totransform life sciences—and for millions of people, even life itself.
The IBRI provides equal employment opportunities to allemployees and applicants and does not discriminate based on age, race, color,religion, gender, sexual orientation, gender identity, gender expression,national origin, protected veteran status, disability, or any other legallyprotected status.